M

Merlin Nexus

1 employees

Merlin Nexus, based in New York, is a company focused on crossover private equity investing in the life sciences industry.

Investor insights

Sectors invested in

Biotechnology5
Therapeutics3
Health Care3
Pharmaceutical2
Medical2
bispecific antibodies1
Gastric Cancer1
Biliary Tract Cancer1
protein engineering1
Breast Cancer1
antibody therapeutics1
Immune redirection1
ADC1
effector function modulation1
Biopharma1

Funding rounds participated in

$40M sweet spot round size

Most of their 7 investments are in rounds between $30M and $43M

Investor type

Private Equity Firm

Basic info

Date founded

2001

Investments made

Z

Zymeworks Inc. raised $62M on January 8, 2016

Investors: Lumira Ventures, Brace Pharma Capital, Teralys Capital, Perceptive Advisors, Northleaf Capital Partners, Celgene and Merlin Nexus

A

Adaptimmune Ltd raised $104M on September 25, 2014

Investors: Wellington Management, OrbiMed Advisors, venBio Partners, Ridgeback Capital Management LLC, QVT Financial LLP, Novo Holdings, University of Oxford and Merlin Nexus

U

Undisclosed raised $33M on December 16, 2013

Investors: Ridgeback Capital Management LLC, venBio Partners and Merlin Nexus

U

Undisclosed raised $30M on May 31, 2011

Investors: Great Point Partners and Merlin Nexus

S

Sunesis Pharmaceuticals, Inc. raised $44M on April 7, 2009

Investors: Nextech Invest, Opus Point Partners, Alta Partners, Bay City Capital, Venrock and Merlin Nexus

C

Cancervax (merged to Micromet) raised $40M on October 3, 2008

Investors: Index Ventures, Abingworth, DAFNA Capital Management, LLC and Merlin Nexus

X

Xencor raised $15M on October 25, 2007

Investors: Novo Nordisk Ltd and Merlin Nexus

FAQ